Lagos, Nigeria
54gene, founded in 2019 and headquartered in Nigeria, is a pioneering company within the Biotechnology, Health Care, and Life Sciences sectors. With the slogan “Equalizing Precision Medicine,” the company addresses a critical imbalance in the global genomics market, where less than 2% of genetic material used in pharmaceutical research is African. This is despite the continent's rich genetic diversity, which holds untapped potential for medical breakthroughs.
The company's mission to bridge this genomic gap is vital for inclusive pharmaceutical research and development. However, recent financial challenges culminated in a bankruptcy situation, leading to an investment in September 2023 aimed at sustaining operations. The absence of disclosed investor names during this financing round could be a concern for prospective stakeholders. Nevertheless, 54gene represents a unique opportunity for investors focusing on underrepresented markets with significant growth potential in healthcare innovation.
